{"nctId":"NCT04127786","briefTitle":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","startDateStruct":{"date":"2019-10-21","type":"ACTUAL"},"conditions":["Rabies","Healthy Volunteers"],"count":1708,"armGroups":[{"label":"Group1:VRVg2 Cohort1(C1)-1ry Series:pediatric&adult participants-Booster:102 adult participants","type":"EXPERIMENTAL","interventionNames":["Biological: Purified vero rabies vaccine - serum free - VRVg-2"]},{"label":"Group 2:Verorab C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Purified vero rabies vaccine - serum free - VRVg-2","Biological: Purified inactivated rabies vaccine - Verorab®"]},{"label":"Group 3:Imovax Rabies C1-1ry Series:pediatric&adult participants-Booster Phase:34 adult participants","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Purified vero rabies vaccine - serum free - VRVg-2","Biological: Purified inactivated rabies vaccine - Imovax® Rabies"]},{"label":"Group 4:VRVg-2 Cohort 2(C2)-1ry Series:Adult participants-Booster Phase:138 adult participants","type":"EXPERIMENTAL","interventionNames":["Biological: Purified vero rabies vaccine - serum free - VRVg-2"]},{"label":"Group 5:Verorab C2-1ry Series:adult participants-Booster Phase:46 adult participants","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Purified vero rabies vaccine - serum free - VRVg-2","Biological: Purified inactivated rabies vaccine - Verorab®"]},{"label":"Group 6:Imovax Rabies C2-1ry Series:adult participants-Booster Phase:46 adult participants","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Purified vero rabies vaccine - serum free - VRVg-2","Biological: Purified inactivated rabies vaccine - Imovax® Rabies"]}],"interventions":[{"name":"Purified vero rabies vaccine - serum free - VRVg-2","otherNames":[]},{"name":"Purified inactivated rabies vaccine - Verorab®","otherNames":[]},{"name":"Purified inactivated rabies vaccine - Imovax® Rabies","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged ≥1 year on the day of inclusion\n\n  * Cohort 1 - pediatrics (\\>1 to 17 years old) and adult (≥18 years old)\n  * Cohort 2 - all adults (≥18 years old)\n* Informed consent form has been signed and dated by the participant and /or and parent(s) or legally acceptable representative (LAR) and by an independent witness (if required by local regulations), as necessary; and assent form has been signed and dated by the participant, as required\n* Participant (adult ≥18 years) or participant and parent/LAR (1 year to \\<18 years) are able to attend all scheduled visits and to comply with all study procedures.\n\nExclusion Criteria:\n\n* Participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until 1 month after each vaccination. To be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, or surgically sterile.\n* Participation at the time of study enrollment or, planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.\n* Receipt of any vaccine in the 4 weeks (28 days) preceding the first study vaccination or planned receipt of any vaccine prior to Visit 5 for pediatric participants and adult participants in Cohort 1, and prior to Visit 4 for adult participants in Cohort 2.\n* Previous vaccination against rabies (in pre- or post-exposure regimen) with either the study vaccines or another vaccine.\n* Bite by, or exposure to a potentially rabid animal in the previous 6 months with or without post-exposure prophylaxis.\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months.\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* At high risk for rabies exposure during the study.\n* Known systemic hypersensitivity to any of the study/control vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances.\n* Self-reported thrombocytopenia, contraindicating intramuscular vaccination.\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n* Current alcohol or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion.\n* Chronic illness(1) that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion.\n* Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.\n* Personal history of Guillain-Barré syndrome.\n* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.\n\n  1. Chronic illness may include, but is not limited to, neurological, cardiopulmonary, gastrointestinal, renal, genitourinary, metabolic, hematologic, auto-immune, or psychiatric disorders or infection","healthyVolunteers":true,"sex":"ALL","minimumAge":"1 Year","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to (>=) 0.5 IU/mL","description":"RVNA titer against rabies virus was assessed using the Rapid Fluorescent Focus Inhibition test (RFFIT) assay method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98.8","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.5 IU/mL","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.5 IU/mL - Pooled Population","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. At Baseline, Group 1 was equivalent to Group 4 (both groups received VRVg-2), Group 2 was equivalent to Group 5 (both groups received Verorab®), and Group 3 was equivalent to Group 6 (both groups received Imovax Rabies®), therefore it was planned to collect and present pooled data of specified Groups, and separately for adults and pediatric participants in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null},{"groupId":"OG001","value":"98.5","spread":null},{"groupId":"OG002","value":"96.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.5 IU/mL - Pooled Population (Groups 1 and 4) Versus Cohort 1: Group 3: Non-inferiority Analysis","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. At Baseline, Group 1 was equivalent to Group 4 (both groups received VRVg-2), therefore it was planned to collect and present pooled data of specified Group, and separately for adults and pediatric participants in this outcome measure. Data for this outcome measure was planned to be collected at Day 28 for Pooled Groups 1 and 4 and at Day 42 for Primary Series: Cohort-1 Group 3: Imovax Rabies® and reported as overall data for the non-inferiority analysis in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series: Groups 1 and 4: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.5 IU/mL - Pooled Population - Superiority Analysis","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. At Baseline, Group 1 was equivalent to Group 4 (both groups received VRVg-2), therefore it was planned to collect and present pooled data of specified Group in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 1 Group 3: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.5 IU/mL - Non-Inferiority Analysis","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 1: Rabies Virus Neutralizing Antibody Geometric Mean Titers (GMTs) Against Rabies Virus","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.100","spread":null},{"groupId":"OG001","value":"0.101","spread":null},{"groupId":"OG002","value":"0.101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.16","spread":null},{"groupId":"OG001","value":"4.90","spread":null},{"groupId":"OG002","value":"5.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"16.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 2: Rabies Virus Neutralizing Antibody Geometric Mean Titers (GMTs) Against Rabies Virus","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.101","spread":null},{"groupId":"OG001","value":"0.101","spread":null},{"groupId":"OG002","value":"0.100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.79","spread":null},{"groupId":"OG001","value":"2.92","spread":null},{"groupId":"OG002","value":"3.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.5 IU/mL","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"98.3","spread":null},{"groupId":"OG002","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.2 IU/mL (Lower Limit of Quantification [LLOQ])","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. LLOQ for the RFFIT assay was 0.2 IU/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.2 IU/mL (Lower Limit of Quantification [LLOQ])","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. LLOQ for the RFFIT assay was 0.2 IU/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"98.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 1: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs post-vaccination (i.e., on Day 28 and Day 42) and pre-vaccination on Day 0.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","spread":null},{"groupId":"OG001","value":"48.7","spread":null},{"groupId":"OG002","value":"51.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"240","spread":null},{"groupId":"OG001","value":"199","spread":null},{"groupId":"OG002","value":"163","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 2: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs post-vaccination (i.e., on Day 28) and pre-vaccination on Day 0.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null},{"groupId":"OG001","value":"29.0","spread":null},{"groupId":"OG002","value":"38.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 1: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization","description":"Virus neutralization was defined as complete (absence of fluorescent cells) and incomplete (presence of fluorescent cells) at the participant/timepoint level at the starting dilution (1/5) of RFFIT assay. Percentage of participants with determined complete and determined incomplete virus neutralization were reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"98.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.4","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Primary Series Cohort 2: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization","description":"Virus neutralization was defined as complete (absence of fluorescent cells) and incomplete (presence of fluorescent cells) at the participant/timepoint level at the starting dilution (1/5) of RFFIT assay. Percentage of participants with determined complete and determined incomplete virus neutralization were reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"4.2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null},{"groupId":"OG001","value":"95.8","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"98.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Booster Phase: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.679","spread":null},{"groupId":"OG001","value":"0.540","spread":null},{"groupId":"OG002","value":"0.487","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"57.1","spread":null},{"groupId":"OG002","value":"33.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Booster Phase: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.5 IU/mL","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"53.8","spread":null},{"groupId":"OG002","value":"35.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Booster Phase: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers >=0.2 IU/mL (LLOQ)","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. LLOQ for the RFFIT assay was 0.2 IU/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null},{"groupId":"OG001","value":"76.9","spread":null},{"groupId":"OG002","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Booster Phase: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers","description":"RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs post vaccination (i.e., on Month 12 and Month 12 + Day 14) and pre-vaccination on Day 0, pre-booster dose on Month 12.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.79","spread":null},{"groupId":"OG001","value":"5.40","spread":null},{"groupId":"OG002","value":"4.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"565","spread":null},{"groupId":"OG001","value":"571","spread":null},{"groupId":"OG002","value":"331","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"69.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Booster Phase: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization","description":"Virus neutralization was defined as complete (absence of fluorescent cells) and incomplete (presence of fluorescent cells) at the participant/timepoint level at the starting dilution (1/5) of RFFIT assay. Percentage of participants with determined complete and determined incomplete virus neutralization were reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null},{"groupId":"OG001","value":"84.0","spread":null},{"groupId":"OG002","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"16.0","spread":null},{"groupId":"OG002","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Immediate Unsolicited Adverse Events (AEs)","description":"An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessarily had to have a causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset post-vaccination. All participants were observed for 30 minutes after any vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRB.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Immediate Unsolicited Adverse Events (AEs) - Booster Phase Cohort-2","description":"An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessarily had to have a causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset post-vaccination. All participants were observed for 30 minutes after any vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRB.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants With Systemic Reactions","description":"A SR was an expected AR observed and reported under conditions (nature and onset) pre-listed (i.e., solicited) in the protocol and CRB and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss, irritability, headache, malaise and myalgia. Solicited systemic reactions were collected by different age groups: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability were collected for participants aged 12 to 23 months. Fever, Headache, Malaise and Myalgia were collected for participants aged \\>= 2 years.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"46","spread":null},{"groupId":"OG003","value":"39","spread":null},{"groupId":"OG004","value":"9","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"4","spread":null},{"groupId":"OG007","value":"3","spread":null},{"groupId":"OG008","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"48","spread":null},{"groupId":"OG003","value":"37","spread":null},{"groupId":"OG004","value":"10","spread":null},{"groupId":"OG005","value":"12","spread":null},{"groupId":"OG006","value":"8","spread":null},{"groupId":"OG007","value":"3","spread":null},{"groupId":"OG008","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"249","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"78","spread":null},{"groupId":"OG003","value":"78","spread":null},{"groupId":"OG004","value":"12","spread":null},{"groupId":"OG005","value":"29","spread":null},{"groupId":"OG006","value":"23","spread":null},{"groupId":"OG007","value":"9","spread":null},{"groupId":"OG008","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Systemic Reactions - Booster Phase Cohort-2","description":"A SR was an expected AR observed and reported under conditions (nature and onset) pre-listed (i.e., solicited) in the protocol and CRB and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss, irritability, headache, malaise and myalgia. Solicited systemic reactions were collected by different age groups: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability were collected for participants aged 12 to 23 months. Fever, Headache, Malaise and Myalgia were collected for participants aged \\>= 2 years.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants With Solicited Injection Site Reactions","description":"A solicited reaction (SR) was an expected AR observed and reported under conditions (nature and onset) pre-listed (i.e., solicited) in the protocol and CRB and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited injection site reactions included tenderness/pain, erythema and swelling.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"106","spread":null},{"groupId":"OG003","value":"111","spread":null},{"groupId":"OG004","value":"30","spread":null},{"groupId":"OG005","value":"43","spread":null},{"groupId":"OG006","value":"44","spread":null},{"groupId":"OG007","value":"12","spread":null},{"groupId":"OG008","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Injection Site Reactions - Booster Phase Cohort-2","description":"A solicited reaction (SR) was an expected AR observed and reported under conditions (nature and onset) pre-listed (i.e., solicited) in the protocol and CRB and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited injection site reactions included tenderness/pain, erythema and swelling.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited Adverse Events","description":"An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessarily had to have a causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the CRB in terms of diagnosis and/or onset post-vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"40","spread":null},{"groupId":"OG003","value":"44","spread":null},{"groupId":"OG004","value":"18","spread":null},{"groupId":"OG005","value":"12","spread":null},{"groupId":"OG006","value":"13","spread":null},{"groupId":"OG007","value":"3","spread":null},{"groupId":"OG008","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited Adverse Events - Booster Phase Cohort-2","description":"An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessarily had to have a causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the CRB in terms of diagnosis and/or onset post-vaccination.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)","description":"An SAEs was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or a medically important event. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. All SAEs and AESIs occurring during the study that were related to the product administered were reported by the Investigator to the Independent Ethics Committee/Institutional Review Board. Relatedness to study vaccine was based on Investigator's discretion.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) - Booster Phase Cohort-2","description":"An SAEs was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or a medically important event. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. All SAEs and AESIs occurring during the study that were related to the product administered were reported by the Investigator to the Independent Ethics Committee/Institutional Review Board. Relatedness to study vaccine was based on Investigator's discretion.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":607},"commonTop":["Injection Site Pain","Myalgia","Malaise","Headache","Pyrexia"]}}}